312 related articles for article (PubMed ID: 15491144)
1. Role of inhibitor aliphatic chain in the thermodynamics of inhibitor binding to Escherichia coli enoyl-ACP reductase and the Phe203Leu mutant: a proposed mechanism for drug resistance.
Protasevich II; Brouillette CG; Snow ME; Dunham S; Rubin JR; Gogliotti R; Siegel K
Biochemistry; 2004 Oct; 43(42):13380-9. PubMed ID: 15491144
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity studies of the inhibition of FabI, the enoyl reductase from Escherichia coli, by triclosan: kinetic analysis of mutant FabIs.
Sivaraman S; Zwahlen J; Bell AF; Hedstrom L; Tonge PJ
Biochemistry; 2003 Apr; 42(15):4406-13. PubMed ID: 12693936
[TBL] [Abstract][Full Text] [Related]
3. A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-ACP reductase.
Levy CW; Baldock C; Wallace AJ; Sedelnikova S; Viner RC; Clough JM; Stuitje AR; Slabas AR; Rice DW; Rafferty JB
J Mol Biol; 2001 May; 309(1):171-80. PubMed ID: 11491286
[TBL] [Abstract][Full Text] [Related]
4. Kinetic determinants of the interaction of enoyl-ACP reductase from Plasmodium falciparum with its substrates and inhibitors.
Kapoor M; Dar MJ; Surolia A; Surolia N
Biochem Biophys Res Commun; 2001 Dec; 289(4):832-7. PubMed ID: 11735121
[TBL] [Abstract][Full Text] [Related]
5. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
Seefeld MA; Miller WH; Newlander KA; Burgess WJ; DeWolf WE; Elkins PA; Head MS; Jakas DR; Janson CA; Keller PM; Manley PJ; Moore TD; Payne DJ; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Uzinskas IN; Wallis NG; Huffman WF
J Med Chem; 2003 Apr; 46(9):1627-35. PubMed ID: 12699381
[TBL] [Abstract][Full Text] [Related]
6. The X-ray structure of Escherichia coli enoyl reductase with bound NAD+ at 2.1 A resolution.
Baldock C; Rafferty JB; Stuitje AR; Slabas AR; Rice DW
J Mol Biol; 1998 Dec; 284(5):1529-46. PubMed ID: 9878369
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
Lu H; Tonge PJ
Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
[TBL] [Abstract][Full Text] [Related]
8. Enoyl-ACP reductase (FabI) of Haemophilus influenzae: steady-state kinetic mechanism and inhibition by triclosan and hexachlorophene.
Marcinkeviciene J; Jiang W; Kopcho LM; Locke G; Luo Y; Copeland RA
Arch Biochem Biophys; 2001 Jun; 390(1):101-8. PubMed ID: 11368521
[TBL] [Abstract][Full Text] [Related]
9. The enoyl-[acyl-carrier-protein] reductase (FabI) of Escherichia coli, which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA.
Bergler H; Fuchsbichler S; Högenauer G; Turnowsky F
Eur J Biochem; 1996 Dec; 242(3):689-94. PubMed ID: 9022698
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues.
Sivaraman S; Sullivan TJ; Johnson F; Novichenok P; Cui G; Simmerling C; Tonge PJ
J Med Chem; 2004 Jan; 47(3):509-18. PubMed ID: 14736233
[TBL] [Abstract][Full Text] [Related]
11. Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.
Kitagawa H; Ozawa T; Takahata S; Iida M; Saito J; Yamada M
J Med Chem; 2007 Sep; 50(19):4710-20. PubMed ID: 17713898
[TBL] [Abstract][Full Text] [Related]
12. Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers.
Yao J; Zhang Q; Min J; He J; Yu Z
Bioorg Med Chem Lett; 2010 Jan; 20(1):56-9. PubMed ID: 19959361
[TBL] [Abstract][Full Text] [Related]
13. 4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI.
Kitagawa H; Kumura K; Takahata S; Iida M; Atsumi K
Bioorg Med Chem; 2007 Jan; 15(2):1106-16. PubMed ID: 17095231
[TBL] [Abstract][Full Text] [Related]
14. Cephalochromin, a FabI-directed antibacterial of microbial origin.
Zheng CJ; Sohn MJ; Lee S; Hong YS; Kwak JH; Kim WG
Biochem Biophys Res Commun; 2007 Nov; 362(4):1107-12. PubMed ID: 17825252
[TBL] [Abstract][Full Text] [Related]
15. Three-dimensional structure of Escherichia coli dihydrodipicolinate reductase in complex with NADH and the inhibitor 2,6-pyridinedicarboxylate.
Scapin G; Reddy SG; Zheng R; Blanchard JS
Biochemistry; 1997 Dec; 36(49):15081-8. PubMed ID: 9398235
[TBL] [Abstract][Full Text] [Related]
16. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
[TBL] [Abstract][Full Text] [Related]
17. Crystallization and preliminary X-ray diffraction studies of the enoyl-ACP reductase from Escherichia coli.
Wagner UG; Bergler H; Fuchsbichler S; Turnowsky F; Högenauer G; Kratky C
J Mol Biol; 1994 Oct; 243(1):126-7. PubMed ID: 7932735
[TBL] [Abstract][Full Text] [Related]
18. Exploring the interaction energies for the binding of hydroxydiphenyl ethers to enoyl-acyl carrier protein reductases.
Muralidharan J; Suguna K; Surolia A; Surolia N
J Biomol Struct Dyn; 2003 Feb; 20(4):589-94. PubMed ID: 12529157
[TBL] [Abstract][Full Text] [Related]
19. The enoyl-[acyl-carrier-protein] reductases FabI and FabL from Bacillus subtilis.
Heath RJ; Su N; Murphy CK; Rock CO
J Biol Chem; 2000 Dec; 275(51):40128-33. PubMed ID: 11007778
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a novel enoyl-acyl carrier protein reductase of diazaborine-resistant Rhodobacter sphaeroides mutant.
Lee IH; Kim EJ; Cho YH; Lee JK
Biochem Biophys Res Commun; 2002 Dec; 299(4):621-7. PubMed ID: 12459184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
